Immunomodulator Platform
Ovarian Cancer
Key Facts
About OmniCyte
OmniCyte is a private, preclinical biotech founded in 2018, developing a novel platform of recombinant targeted immunomodulators (co-stimulators) for cancer therapy. The company boasts a scientifically distinguished team and advisory board with deep expertise in oncology and immunology, including pioneers of the PD-1/PD-L1 field. It is initially targeting ovarian cancer and small cell lung cancer, with funding from grants, state innovation funds, and angel investors.
View full company profileAbout OmniCyte
OmniCyte is a private, preclinical biotech founded in 2018, developing a novel platform of recombinant targeted immunomodulators (co-stimulators) for cancer therapy. The company boasts a scientifically distinguished team and advisory board with deep expertise in oncology and immunology, including pioneers of the PD-1/PD-L1 field. It is initially targeting ovarian cancer and small cell lung cancer, with funding from grants, state innovation funds, and angel investors.
View full company profileAbout OmniCyte
OmniCyte is a private, preclinical biotech founded in 2018, developing a novel platform of recombinant targeted immunomodulators (co-stimulators) for cancer therapy. The company boasts a scientifically distinguished team and advisory board with deep expertise in oncology and immunology, including pioneers of the PD-1/PD-L1 field. It is initially targeting ovarian cancer and small cell lung cancer, with funding from grants, state innovation funds, and angel investors.
View full company profileAbout OmniCyte
OmniCyte is a private, preclinical biotech founded in 2018, developing a novel platform of recombinant targeted immunomodulators (co-stimulators) for cancer therapy. The company boasts a scientifically distinguished team and advisory board with deep expertise in oncology and immunology, including pioneers of the PD-1/PD-L1 field. It is initially targeting ovarian cancer and small cell lung cancer, with funding from grants, state innovation funds, and angel investors.
View full company profileAbout OmniCyte
OmniCyte is a private, preclinical biotech founded in 2018, developing a novel platform of recombinant targeted immunomodulators (co-stimulators) for cancer therapy. The company boasts a scientifically distinguished team and advisory board with deep expertise in oncology and immunology, including pioneers of the PD-1/PD-L1 field. It is initially targeting ovarian cancer and small cell lung cancer, with funding from grants, state innovation funds, and angel investors.
View full company profileAbout OmniCyte
OmniCyte is a private, preclinical biotech founded in 2018, developing a novel platform of recombinant targeted immunomodulators (co-stimulators) for cancer therapy. The company boasts a scientifically distinguished team and advisory board with deep expertise in oncology and immunology, including pioneers of the PD-1/PD-L1 field. It is initially targeting ovarian cancer and small cell lung cancer, with funding from grants, state innovation funds, and angel investors.
View full company profileAbout OmniCyte
OmniCyte is a private, preclinical biotech founded in 2018, developing a novel platform of recombinant targeted immunomodulators (co-stimulators) for cancer therapy. The company boasts a scientifically distinguished team and advisory board with deep expertise in oncology and immunology, including pioneers of the PD-1/PD-L1 field. It is initially targeting ovarian cancer and small cell lung cancer, with funding from grants, state innovation funds, and angel investors.
View full company profileTherapeutic Areas
Other Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| EXO‑Ovarian Cancer Test | INOVIQ | Phase 2/3 |
| CAR‑iNK‑OvCa | Cartherics | Preclinical |
| MagSense™ FR Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Yondelis (trabectedin) | PharmaMar | Approved |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| NP-G2-044 + Chemotherapy Agents | Novita Pharmaceuticals | Phase 2a |
| Ivospemin (SBP-101) | Panbela Therapeutics | Phase 2 |
| Ovarian Cancer Early Detection Assay | GenEndeavor | Pre-clinical |
| INVAC-1 | Invectys | Phase 2 |
| Folate Receptor-Targeted PCC | Indi Molecular | Preclinical |
| Platform Candidate | FLAG Therapeutics | Preclinical |
| High Internalization ADC | Lytica Therapeutics | Preclinical |